Story
Nanexa Stock Surges Over 110% on €1.17 Billion Licensing Deal with Novo Nordisk
Summary
Shares of Swedish biotech Nanexa more than doubled after the company announced a global licensing agreement with Novo Nordisk, potentially worth up to €1.165 billion, for its long-acting drug-delivery technology.
Shares of Swedish biotechnology firm Nanexa AB (NANEXA) surged more than 114% in trading on Tuesday after the company announced a major global licensing agreement with pharmaceutical giant Novo Nordisk (NVO). The deal, centered on Nanexa's proprietary PharmaShell drug-delivery platform, has a potential total value of up to €1.165 billion.
Agreement Details
The agreement grants Novo Nordisk an exclusive worldwide license to utilize Nanexa’s PharmaShell technology for up to five development programs. The technology is aimed at creating long-acting treatments for obesity, type 2 diabetes, and other cardiometabolic diseases.
According to the announcement, the collaboration's goal is to enable once-monthly or even once-quarterly dosing for peptide-based drugs, a significant potential improvement over the current weekly injection schedules common for GLP-1 therapies. The financial terms of the deal include:
- Upfront and development-related milestone payments totaling €615 million.
- Additional milestone payments tied to sales, bringing the potential total to €1.165 billion.
- A low single-digit royalty on global net sales of any resulting products.
AdNovo Nordisk will be responsible for all global development and commercialization efforts under the agreement.
Market Impact and Context
The market’s reaction was swift and dramatic, with Nanexa's stock price soaring at the market open on September 25, following the deal's publication the prior evening. The move reflects investor recognition of the deal as a transformative event for the smaller Uppsala-based company.
This agreement provides significant external validation for Nanexa's PharmaShell platform, which uses atomic layer deposition (ALD) to control drug release. It builds upon a previous licensing deal the company signed with Moderna in late 2025. For investors, the partnership with a market leader like Novo Nordisk not only de-risks Nanexa's technology but also provides a substantial financial runway, fundamentally altering the company's valuation and outlook.
Read next
More on Stocks
BMO Says AI Safety Concerns Unlikely to Slow Pace of Frontier Development
Despite genuine safety fears among industry leaders, top AI labs show little sign of slowing the release of more powerful models, according to a BMO note.
European Stocks Gain as Oil Price Dip Eases Sting of Surging Bond Yields
European markets advanced Friday, with a pullback in crude oil prices providing relief for key sectors. The gains came despite a continued surge in government bond yields, which have reached multi-year highs on expectations of prolonged central bank tightening.
Nikkei 225 Jumps 1.45% to One-Month High on Broad Sector Gains
Japanese stocks closed higher on Friday, with the Nikkei 225 index climbing 1.45% to reach its highest level in a month, driven by strong performance in the real estate and banking sectors.
HSBC Upgrades BP and TotalEnergies to Buy on Bullish Oil and Gas Forecasts
HSBC upgraded BP and TotalEnergies to Buy, raising its price forecasts for Brent crude and natural gas, which led to significantly higher earnings estimates across the energy sector.